NAD+ · research summary

Novel applications of SIRT1 in Chronic Kidney Disease.

Frontiers in medicine · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Systematic review of mechanisms and therapeutic strategies
“This review systematically elaborates on the mechanisms regulating SIRT1 expression and activity in CKD, its protective roles in core pathological processes, and summarizes recent advances in targeting SIRT1 for CKD therapy.”

Subjects

Chronic kidney disease pathology, SIRT1 molecular mechanisms, and preclinical/clinical trial data
“This review systematically elaborates on the mechanisms regulating SIRT1 expression and activity in CKD, its protective roles in core pathological processes, and summarizes recent advances in targeting SIRT1 for CKD therapy.”

Reported findings

SIRT1 antagonizes kidney fibrosis by deacetylating Smad3/Smad4 and inhibiting epithelial-mesenchymal transition.
“Functionally, SIRT1 antagonizes kidney fibrosis by deacetylating Smad3/Smad4 and inhibiting epithelial-mesenchymal transition.”
SIRT1 curbs inflammatory cascades through dual blockade of NF-κB transcriptional activity and NLRP3 inflammasome assembly.
“Functionally, SIRT1 antagonizes kidney fibrosis by deacetylating Smad3/Smad4 and inhibiting epithelial-mesenchymal transition; curbs inflammatory cascades through dual blockade of NF-κB transcriptional activity and NLRP3 inflammasome assembly.”
The synthetic SIRT1 agonist SRT2104 has completed Phase I-II clinical trials with favorable safety profiles.
“In terms of therapeutic strategies, the synthetic SIRT1 agonist SRT2104 has completed Phase I-II clinical trials with favorable safety profiles, but its pharmacokinetic limitations and the disconnect from preclinical effects pose barriers to clinical translation.”

Limitations stated by the authors

Pharmacokinetic limitations of SRT2104 and lack of clinical evidence for NAD+ precursors in CKD populations.
“In terms of therapeutic strategies, the synthetic SIRT1 agonist SRT2104 has completed Phase I-II clinical trials with favorable safety profiles, but its pharmacokinetic limitations and the disconnect from preclinical effects pose barriers to clinical translation; NAD⁺ precursor strategies offer theoretical advantages but lack clinical evidence in CKD populations.”

Source: PubMed 42846585 · DOI 10.3389/fmed.2026.1922310 · all study summaries

Subjects

Chronic kidney disease pathology, SIRT1 molecular mechanisms, and preclinical/clinical trial data

“This review systematically elaborates on the mechanisms regulating SIRT1 expression and activity in CKD, its protective roles in core pathological processes, and summarizes recent advances in targeting SIRT1 for CKD therapy.”

Reported findings

SIRT1 antagonizes kidney fibrosis by deacetylating Smad3/Smad4 and inhibiting epithelial-mesenchymal transition.

“Functionally, SIRT1 antagonizes kidney fibrosis by deacetylating Smad3/Smad4 and inhibiting epithelial-mesenchymal transition.”

SIRT1 curbs inflammatory cascades through dual blockade of NF-κB transcriptional activity and NLRP3 inflammasome assembly.

“Functionally, SIRT1 antagonizes kidney fibrosis by deacetylating Smad3/Smad4 and inhibiting epithelial-mesenchymal transition; curbs inflammatory cascades through dual blockade of NF-κB transcriptional activity and NLRP3 inflammasome assembly.”

The synthetic SIRT1 agonist SRT2104 has completed Phase I-II clinical trials with favorable safety profiles.

“In terms of therapeutic strategies, the synthetic SIRT1 agonist SRT2104 has completed Phase I-II clinical trials with favorable safety profiles, but its pharmacokinetic limitations and the disconnect from preclinical effects pose barriers to clinical translation.”

Limitations stated by the authors

Pharmacokinetic limitations of SRT2104 and lack of clinical evidence for NAD+ precursors in CKD populations.

“In terms of therapeutic strategies, the synthetic SIRT1 agonist SRT2104 has completed Phase I-II clinical trials with favorable safety profiles, but its pharmacokinetic limitations and the disconnect from preclinical effects pose barriers to clinical translation; NAD⁺ precursor strategies offer theoretical advantages but lack clinical evidence in CKD populations.”